Tony Johnson, Goldfinch Bio CEO (Goldfinch via YouTube)
Kidney disease drugmaker Goldfinch Bio shuts down
Goldfinch Bio, attempting to make treatments for kidney diseases and diabetic nephropathy, is shutting down.
President and CEO Tony Johnson confirmed to Endpoints News Friday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.